Transcriptional Phenocopies of Deleterious KEAP1 Mutations Correlate with Survival Outcomes in Lung Cancer Treated with Immunotherapy.

doi:10.1158/1078-0432.CCR-24-0626

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Transcriptional Phenocopies of Deleterious KEAP1 Mutations Correlate with Survival Outcomes in Lung Cancer Treated with Immunotherapy.

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Oct 2024

Scalera Stefano, Ricciuti Biagio, Marinelli Daniele, Mazzotta Marco, Cipriani Laura, Bon Giulia, Schiavoni Giulia, Terrenato Irene, Di Federico Alessandro, Alessi Joao V, Fanciulli Maurizio, Ciuffreda Ludovica, De Nicola Francesca, Goeman Frauke, Caravagna Giulio, Santini Daniele, De Maria Ruggero, Cappuzzo Federico, Ciliberto Gennaro, Jamal-Hanjani Mariam, Awad Mark M, McGranahan Nicholas, Maugeri-Saccà Marcello

Abstract excerpt

PURPOSE: Co-occurring mutations in KEAP1 and STK11/KRAS have emerged as determinants of survival outcomes in patients with non-small cell lung cancer (NSCLC) treated with immunotherapy. However, these mutational contexts identify a fraction of nonresponders to immune checkpoint inhibitors. We hypothesized that KEAP1 wild-type tumors recapitulate the transcriptional footprint of KEAP1 mutations and that this...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Non-Small-Cell Lung

Share to Gene Expression Regulation, Neoplastic

Share to Immunotherapy

Share to Kelch-Like ECH-Associated Protein 1

Share to Lung Neoplasms

Share to Phenotype

Share to Prognosis

Source

Open in PubMed

Identifiers

PMID: 38980931
DOI: 10.1158/1078-0432.CCR-24-0626

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Transcriptional Phenocopies of Deleterious KEAP1 Mutations Correlate with Survival Outcomes in Lung Cancer Treated with Immunotherapy.PMID 38980931Read ↗

Transcriptional phenocopies of deleterious<i>KEAP1</i>mutations dictate survival outcomes in lung cancer treated with immunotherapySemantic proximity Read ↗

KEAP1 and TP53 Frame Genomic, Evolutionary, and Immunologic Subtypes of Lung Adenocarcinoma With Different Sensitivity to Immunotherapy.Semantic proximity Read ↗

KEAP1-driven co-mutations in lung adenocarcinoma unresponsive to immunotherapy despite high tumor mutational burden.Semantic proximity Read ↗

Clonal KEAP1 mutations with loss of heterozygosity share reduced immunotherapy efficacy and low immune cell infiltration in lung adenocarcinoma.Semantic proximity Read ↗

KEAP1 mutation in lung adenocarcinoma promotes immune evasion and immunotherapy resistance.Semantic proximity Read ↗

Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities.Semantic proximity Read ↗

Machine learning-based immune phenotypes correlate with STK11/KEAP1 co-mutations and prognosis in resectable NSCLC: a sub-study of the TNM-I trial.Semantic proximity Read ↗

Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-up.Semantic proximity Read ↗

Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status.Semantic proximity Read ↗

Influence of TP53 Comutation on the Tumor Immune Microenvironment and Clinical Outcomes With Immune Checkpoint Inhibitors in STK11-Mutant Non–Small-Cell Lung CancerSemantic proximity Read ↗

Integrative omics analysis identifies subtypes with therapeutic implications in lung adenocarcinoma harboring KEAP1/NFE2L2Semantic proximity Read ↗

Genetic drivers of tumor microenvironment and immunotherapy resistance in non-small cell lung cancer: the role of KEAP1 , SMARCA4 , and PTEN mutationsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.